GalenOps prod · 0.1.0

Patients

2

Active

0

enrolled or consented

Withdrawn

1

Serious AEs

0

Open QA findings

0

Aged data queries

0

Studies & contracts

total budget 64000.00 USD

A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) Compared to Doxorubicin in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma
Phase II study completed contract executed 64000 USD

Patients first 2

RefStatusConsentedStudy
P2B-096 withdrawn 2013-03-30 A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) Compared to Doxorubicin in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma
P2B-100 completed 2013-04-09 A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) Compared to Doxorubicin in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma

Luna participants 0

No Luna participants yet

Participants at this site have not been invited to Luna.

Safety

8 AEs · 0 serious

No serious adverse events at this site

Non-serious events are listed under Data & Safety.

QA findings

0 open

resolved minor Protocol deviation

CARDIAC ASSESSMENT NOT DONE: Protocol-required ECHO/MUGA after cycle 2 or 4 not performed (subject P2B-100, 2013-07-18)

Monitoring visits 0

No visits recorded

Re-score risk to propose an on-site visit.

Payments 0

No payments on file

Milestone payments are proposed by the finance step and approved in the review queue.